TNFAIP3 Antikörper (AA 525-575)
-
- Target Alle TNFAIP3 Antikörper anzeigen
- TNFAIP3 (Tumor Necrosis Factor, alpha-Induced Protein 3 (TNFAIP3))
-
Bindungsspezifität
- AA 525-575
-
Reaktivität
- Human
-
Wirt
- Kaninchen
-
Klonalität
- Polyklonal
-
Konjugat
- Dieser TNFAIP3 Antikörper ist unkonjugiert
-
Applikation
- Western Blotting (WB), Immunoprecipitation (IP)
- Spezifität
- Region between residue 525 and 575 of human zinc finger protein A20 using the numbering given in entry NP_006281.1 (GeneID 7128).
- Aufreinigung
- Immunoaffinity purified
- Isotyp
- IgG
- Top Product
- Discover our top product TNFAIP3 Primärantikörper
-
-
- Applikationshinweise
- Approved: IP (2 - 5 μg/mg lysate), WB (1:2000 - 1:10000)
- Kommentare
-
Target Species of Antibody: Human
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Liquid
- Konzentration
- Lot specific
- Buffer
- Tris-citrate/phosphate buffer, pH 7-8, 0.09 % sodium azide.
- Konservierungsmittel
- Sodium azide
- Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Lagerung
- 4 °C
- Informationen zur Lagerung
- Store at 2-8°C for up to 1 year.
- Haltbarkeit
- 12 months
-
- Target
- TNFAIP3 (Tumor Necrosis Factor, alpha-Induced Protein 3 (TNFAIP3))
- Andere Bezeichnung
- TNFAIP3 / A20 (TNFAIP3 Produkte)
- Synonyme
- tnfaip3 antikoerper, MGC82339 antikoerper, TNFAIP3 antikoerper, A20 antikoerper, OTUD7C antikoerper, TNFA1P2 antikoerper, Tnfip3 antikoerper, TNF alpha induced protein 3 antikoerper, TNF alpha induced protein 3 S homeolog antikoerper, tumor necrosis factor, alpha-induced protein 3 antikoerper, TNFAIP3 antikoerper, tnfaip3.S antikoerper, Tnfaip3 antikoerper
- Hintergrund
-
Name/Gene ID: TNFAIP3
Synonyms: TNFAIP3, A20, TNFA1P2, TNF alpha-induced protein 3, OTUD7C, Zinc finger protein A20 - Gen-ID
- 7128
- Pathways
- TLR Signalweg, Activation of Innate immune Response, Cellular Response to Molecule of Bacterial Origin, Production of Molecular Mediator of Immune Response
-